B-cell acute lymphoblastic leukemia after lenalidomide maintenance therapy; a deleterious adverse event that needs further investigation. Report of three cases and review of the literature

Leuk Lymphoma. 2023 Oct;64(10):1701-1705. doi: 10.1080/10428194.2023.2234527. Epub 2023 Jul 17.

Authors

I Arribas¹, C Maluquer¹, H Pomares¹, I Carro¹, C Baca¹, A Bosch¹, C E Arévalo¹, C Montané¹, J Ribes-Amorós¹, L Zamora², I Granada², E Gamundi³, M Arnan¹, A Sureda¹

Affiliations

¹ Clinical Hematology Department IDIBELL, Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain.
² Hematology Department, ICO-Hospital Germans Trias i Pujol, José Carreras Leukemia Research Institute, Badalona, Spain.
³ Pathology Department, Bellvitge University Hospital, Barcelona, Spain.

PMID: 37455651
DOI: 10.1080/10428194.2023.2234527

No abstract available

Publication types

Review
Case Reports
Letter

MeSH terms

Humans
Lenalidomide / adverse effects
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*
Thalidomide / adverse effects

Substances

Lenalidomide
Thalidomide